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The treatment of colorectal cancer is rapidly becoming a significant financial burden to health-care systems within economically
developed nations. A current challenge for oncologists and health-care payers is to integrate new, often high-cost, biologic therapies
into clinical practice. Inherent to this process is the consideration of cost-effectiveness. The aim of this study was to compare the cost-
effectiveness of cetuximab plus irinotecan with an appropriate comparator from a National Health Service (NHS) perspective. This
economic evaluation is a trial-based study of cetuximab vs active/best supportive care. Effectiveness estimates for the treatment
groups were modelled from key clinical trials. Cunningham et al (2004) compared cetuximab/irinotecan with cetuximab
monotherapy; Cunningham et al (1998) compared irinotecan monotherapy in a second-line setting with supportive care. Modelling
was necessary owing to an absence of head-to-head clinical trial data of cetuximab/irinotecan vs current standard care. Costs were
calculated for the study drugs received, associated administration, palliative chemotherapy for patients in the standard care arm and
other nonchemotherapy resources. The discounted life-expectancy of patients treated with cetuximab/irinotecan was 0.91 life-years,
and 0.47 discounted life-years for patients receiving active/best supportive care. Patients treated with cetuximab/irinotecan
accumulated mean additional costs of d18901 per patient relative to the comparator arm, with d11802 attributable to cetuximab.
The incremental cost per life-year gained with cetuximab/irinotecan therapy compared with active/best supportive care was d42975.
The incremental cost per quality adjusted life-year gained was d57608. The incremental cost per life-year gained for cetuximab/
irinotecan is relatively high compared with other health-care interventions. However, this result should be considered in the context
of a number of factors specific to the treated patient population.
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Colorectal cancer (CRC) is the third most commonly diagnosed
cancer globally (Parkin, et al, 2001), with almost 30000 new cases
diagnosed in England and Wales per year, representing more than
12% of new cancers diagnosed. About 30% of patients present with
advanced colorectal cancer, defined as either metastatic or locally
invasive disease (NICE, 2005). Advances in the treatment of CRC
in both the adjuvant and metastatic settings have presented
significant financial implications for health-care systems in
economically developed countries.
Treatments for metastatic CRC are mainly palliative and aim to
increase the duration and the quality of the patient’s remaining
life. For many years, 5-fluorouracil (5-FU) was the only active
agent in colorectal cancer associated with survival in the region of
12 months (Metaanalysis, 1994, 1998). Over the last decade
significant progress has been made, as several new chemother-
apeutic agents have been incorporated into routine clinical
practice. Irinotecan, a semisynthetic inhibitor of topoisomerase,
and oxaliplatin, a third-generation platinum compound, were deve-
loped as salvage therapies for patients failing 5-FU (Cunningham
et al, 1998; Rothenberg et al, 2003), and are now established
treatment options for use as first-line, second-line and sequential
treatment in CRC (de Gramont et al, 2000; Douillard et al, 2000;
Saltz et al, 2000; Goldberg et al, 2004; Grothey et al, 2004;
Tournigand et al, 2004). The notion of sequential treatment as a
determinant of survival has become important, with overall
survival of over 21 months now achievable (Tournigand et al,
2004). The National Institute of Health and Clinical Excellence
(NICE) recently approved the sequential use of oxaliplatin and
irinotecan-based chemotherapy in the first- and second-line
treatment of CRC.
Developments in the cytotoxic management of CRC have
progressed in tandem with the clinical development of biologic
agents in CRC. Cetuximab is a monoclonal antibody that targets
the epidermal growth factor receptor (EGFR), which governs
several cellular processes pertinent to tumour development and
progression. In preclinical studies modulating EGFR-mediated
signalling through antibody inhibition resulted in antitumour
activity, the reversal of resistance to irinotecan and synergy with
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sirinotecan (Prewett et al, 2002). In clinical evaluation, two phase II
studies indicated that cetuximab was active in combination with
irinotecan and as monotherapy in irinotecan-resistant patients
(Saltz et al, 2001; Saltz et al, 2004). The Bowel Oncology with
cetuximab aNtiboDy study (BOND; Cunningham et al, 2004)
compared cetuximab in combination with irinotecan against
cetuximab monotherapy in heavily pretreated EGFR-expressing
patients, recording response rates of 23 and 11% respectively, with
a median time to progression favouring the combination arm (4.1
vs 1.5 months, P¼0.0001) (Cunningham et al, 2004). Median
survival was not statistically different between the two arms (8.6 vs
6.9m), which may have been a consequence of crossover. In the
BOND study, patients had received a median of three prior
treatment regimens; 100% of patients had received irinotecan
and 62% of patients had also received prior oxaliplatin. Based on
these results, cetuximab was licensed in Europe for the treatment
of irinotecan-refractory colorectal cancer in combination with
irinotecan in 2005. Given the current NICE guidance for the use of
oxaliplatin and irinotecan, the potential application of cetuximab
in the UK is likely to be in the third-line setting for which there are
currently no standard therapeutic interventions.
The current challenge for oncologists and health-care payers
alike lies in the optimal integration of high-cost biologic therapies
such as cetuximab into clinical practice. Inherent to this process is
the consideration of cost-effectiveness. The aim of this study was
to compare the cost-effectiveness of cetuximab treatment with the
appropriate comparator for the National Health Service (NHS) (i.e.
active/best supportive care). The definition of active/best suppor-
tive care (ASC/BSC) is adapted from the description of supportive
care in a key trial of active chemotherapy vs BSC in the second-line
setting (Cunningham et al, 1998). Active supportive care is defined
as the best care available, as judged by a physician, and may
include chemotherapy. Supportive interventions may include:
antibiotics, analgesics, transfusions, corticosteroids, or any other
symptomatic therapy and/or assistance of a psychotherapist, and
localised radiation therapy (dose within palliative range) to
alleviate symptoms. Best supportive care excludes the possibility
of active chemotherapy.
MATERIALS AND METHODS
The economic evaluation presented is a trial-based study of
cetuximab/irinotecan vs ASC/BSC. This is an indirect comparison
owing to the absence of a direct head-to-head trial of cetuximab
versus ASC/BSC.
Modelling and extrapolation of the clinical trial data were
necessary to quantify the expected costs and benefits of the
respective treatment groups. The economic analysis assessed the
cost-effectiveness of cetuximab/irinotecan in-line with its licensed
indication, for which there are no recognised comparator
treatments established in clinical guidelines.
The primary health outcome for the economic evaluation is life-
years gained (LYG); therefore, the primary health economic
outcome is the incremental cost per life-year gained of cetuximab/
irinotecan vs ASC/BSC. Secondary analyses were performed using
quality adjusted life-years (QALYs) based on utility values directly
observed from a separate clinical trial, the MABEL study, of
cetuximab with irinotecan.
The economic evaluation estimated costs and consequences over
the full lifetime of each patient. Modelling was required to
extrapolate survival curves from the end of the follow-up period
(Cunningham et al, 2004) until all patients were deceased.
Direct costs were estimated from the perspective a third-party
payer (NHS); indirect and intangible costs were not included.
Probabilistic and univariate sensitivity analyses were conducted
for all model parameters in order to demonstrate the robustness of
the results.
Treatments compared
Published clinical evidence was evaluated and a survey of key
medical oncologists in England and Wales was conducted in order
to determine an appropriate comparator (i.e. the treatment
displaced by irinotecan/cetuximab). This research investigation
revealed that patients who fail second-line chemotherapy currently
receive BSC; a minority will receive BSC with cytotoxic
chemotherapy. We defined the treatment received by this late-
stage CRC patient group as active/best supportive care (ASC/BSC).
A key source of published evidence was identified in a trial of
active chemotherapy (irinotecan) vs supportive care in the second-
line setting (Cunningham et al, 1998). Clinical effectiveness and
resource use data for the economic evaluation was taken from the
clinical trials (Cunningham et al, 1998, 2004).
Effectiveness estimates
Effectiveness estimates for the respective treatment groups were
modelled from indirect clinical trial evidence (Cunningham et al,
1998, 2004). The modelling was undertaken, in the absence of head
to head clinical trial data, in order to assess the incremental benefit
of cetuximab/irinotecan compared to ASC/BSC.
Overview of the estimation of survival benefit in the
treatment and comparator groups
The best available evidence on the effectiveness of cetuximab/
irinotecan in this setting is derived from Cunningham et al (2004).
Calculation of the survival benefit of cetuximab/irinotecan therapy
in the economic model requires modelling of Cunningham et al
(2004) trial data for the cetuximab/irinotecan therapy arm. The
economic evaluation compares cetuximab/irinotecan with the
appropriate real-world comparator, ASC/BSC, rather than cetuximab
monotherapy, which was applied in the study (Cunningham et al,
2004). Estimated overall survival benefit for patients receiving
ASC/BSC had to be modelled using the effectiveness data from the
comparator study (Cunningham et al, 1998) to account for the
lower efficacy expected of ASC/BSC, where only a proportion of
patients receive active treatment, compared with the cetuximab
monotherapy patients, where all patients received an active
treatment (Cunningham et al, 2004).
Extrapolation of Cunningham et al (2004) censored
survival data
Survival data for patients who participated in the pivotal
cetuximab/irinotecan study (Cunningham et al, 2004) was imputed
where necessary to account for censored values to allow
calculation of overall life-expectancy in the two treatment arms,
by estimating the missing tail-ends of the survival curves from the
trial database (i.e. some patients were still alive at the end of the
study, making it impossible to calculate average life-expectancy
without some sort of imputation). Standard parametric methods
and multiple imputations were used to formulate the estimates
(Gelber et al, 1993; Parmar et al, 1998). In summary, survival
estimates were separated into three stages:
First stage The expected time for each censored observation was
estimated by adding the predicted value from the parametric
curve, conditioned on the individual’s survival up to the censored
time given that the individual has survived up until the censored
time. The total estimated survival time was calculated as this
quantity plus the censored time.
Second stage Generation of random variables from the assumed
tail distribution to impute the complete censored time. This was
achieved by generating a survival probability from a uniform
distribution of each censored observation; calculating where this
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conditional on the censored time; and adding this quantity to
the censored time. This process is repeated 10 times, producing a
‘filled-in’ data set each time.
Third stage Standard multiple imputation methods use each
filled-in data set in a separate intended analysis and combine the
required results based on the individual data sets.
Patients treated with cetuximab/irinotecan recorded an objective
response rate (ORR) of 22.9%. (95% confidence interval (CI):
17.5–29.1) and a disease control rate (DCR) of 55.5% (95% CI:
48.6–62.2). The median overall survival of patients in the
cetuximab/irinotecan group was 8.6 months in the trial
(Cunningham et al, 2004).
Estimation of survival benefit in the ASC/BSC comparator
group
The current lack of direct comparative evidence for patients
receiving ASC/BSC supports the extrapolation of treatment benefit
based on the best available clinical evidence (Cunningham et al,
1998, 2004). Determination of an appropriate methodology to
estimate survival benefit in the ASC/BSC treatment group was
largely driven by the aim of maintaining the integrity of the clinical
trial data from the pivotal study (Cunningham et al, 2004).
The methodological approach chosen to estimate the expected
treatment benefit of cetuximab/irinotecan in the third-line setting
used survival data for cetuximab monotherapy, together with the
published and established relationship between active cytotoxic
chemotherapy and ASC/BSC in the second-line setting. This trial
(Cunningham et al, 1998) was appropriate for modelling because
the comparator arm reflected ASC/BSC in current clinical practice
(i.e. 31% of the patients in the supportive care arm received
palliative chemotherapy).
The mean life-expectancy of patients receiving cetuximab
monotherapy (Cunningham et al, 2004) was adjusted for censored
patients and inclusion of LYG beyond the follow-up period.
This estimate of survival benefit was factored down to account
for the expected treatment benefit conferred by active cytotoxic
therapy. The factor applied was generated from clinical data
(Cunningham et al, 1998). The relationship in the second-line
setting between the survival benefit experienced by patients treated
with active chemotherapy (irinotecan) and the survival benefit
experienced by those treated with ASC/BSC was summarised in the
form of a survival hazard ratio statistic as indicated by Table 1.
Resource utilisation and cost data
Costs were calculated for the following resources:
  Study drugs received (cetuximab/irinotecan) and associated
administration of drugs.
  Palliative chemotherapy for patients in the ASC/BSC arm.
  Nonchemotherapy resources while a patient is treated with
cetuximab/irinotecan.
  Nonchemotherapy resources while a patient is treated with
palliative chemotherapy in the ASC/BSC arm.
  Nonchemotherapy resources while a patient is not receiving any
chemotherapy (in either arm).
Costs of study drugs and associated administration costs
received by patients in the cetuximab/irinotecan arm were
extracted from the pivotal trial (Cunningham et al, 2004). Owing
to limitations in the literature detailing BSC costs in this patient
population, resource utilisation estimates were extracted from 43
patients who were eligible for inclusion into the pivotal cetuximab
study (Cunningham et al, 2004), but were not enrolled because
recruitment had been completed (Data on File, UKECRC05019).
Patient resource utilisation data for chemotherapy, in-patient
hospitalisations, outpatient consultations, laboratory tests (includ-
ing EGFR testing) and imaging techniques were measured and
costed for use in the model. Average weekly nonchemotherapy
costs were calculated for patients treated with cetuximab/
irinotecan, as well as for patients treated with other chemo-
therapies.
In summary, costs were accumulated in the economic model
using the following methods:
  Cetuximab/irinotecan costs were calculated according to the
amount of drug prescribed in the pivotal study (Cunningham
et al, 2004). All patients had discontinued study drug by the end
of the follow-up period.
  Patients treated with cetuximab/irinotecan accumulated admin-
istration costs of d255.54 per administration day, with the
number of administration days determined from the pivotal
cetuximab/irinotecan study (Cunningham et al, 2004).
  Patients treated with cetuximab/irinotecan accumulated the cost
of a CT scan at 6 weeks (d49.01).
  Patients treated with cetuximab/irinotecan accumulated non-
chemotherapy costs of d59.70 per week while they remained on
treatment.
  Patients in the cetuximab/irinotecan treatment group accumu-
lated nonchemotherapy costs of d50.00 per week after the
disease progressed, and they were no longer on chemotherapy.
  A proportion of patients (31%) in the ASC/BSC group
accumulated chemotherapy costs of d5327 per patient and
associated administration costs of chemotherapy of d1482 per
patient.
  Patients in the ASC/BSC group who received palliative
chemotherapy accumulated nonchemotherapy costs of d50.00
per week until death.
  Patients in the ASC/BSC treatment group who did not receive
palliative chemotherapy also accumulated nonchemotherapy
costs of d50.00 per week until death.
Table 1 Estimating survival in the ASC/BSC treatment group
Row Parameter Value Reference
A Mean survival in patients treated with cetuximab
monotherapy in the BOND study
9.64 months Analysed using individual patient data, including adjustments for
censored patients
B Survival hazard ratio for irinotecan-treated patients relative to
best supportive care patients in a second-line setting
1.71 Cunningham et al (1998)
C Survival hazard ratio for cetuximab monotherapy-treated patients
relative to best supportive care patients
1.71 Assumption that effect of cetuximab monotherapy in the third-line setting
will be the same as irinotecan treatment effect in the second-line setting
(as observed, row B)
D Mean survival in patients in ‘usual care’ for the patients treated with
cetuximab monotherapy in the BOND study
5.64 months A/C. Netting out the cetuximab monotherapy effect in row C from the
monotherapy cetuximab survival observed in BOND (row A)
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Effectiveness estimates
The mean life-expectancy of patients receiving cetuximab/
irinotecan, after adjustments for censored patients and inclusion
of LYG beyond the follow-up period, was 11.01 months. Following
adjustments for censored patients and inclusion of LYG beyond
the follow-up period, the mean life-expectancy of patients
receiving cetuximab monotherapy was 9.64 months (Cunningham
et al, 2004). After factoring this value down to account for the
added treatment effect of active cetuximab monotherapy, the mean
estimated overall survival for patients receiving ASC/BSC was
estimated to be 5.64 months (Table 2). Survival curves of the
respective treatment groups estimated in the model are presented
in Figure 1. The reduced life-expectancy of ASC/BSC patients is
possibly due to the fact that only a minority of patients given ASC/
BSC treatment in England and Wales received active cytotoxic
therapy.
The discounted life-expectancy of patients treated with
cetuximab/irinotecan was 0.91 life-years. This contrasted with
0.47 discounted life-years for patients receiving ASC/BSC. In
summary, cetuximab/irinotecan was associated with an increase in
survival of 0.44 discounted life-years per patient (Table 2).
A secondary analysis calculated the QALYs gained in each of the
treatment groups. The separate cetuximab/irinotecan trial, the
MABEL study, was used to estimate a utility value to apply in this
analysis. The pivotal cetuximab/irinotecan study (Cunningham
et al, 2004) did not collect indexed quality of life outcomes. The
MABEL study collected utility values from 125 patients using the
EQ-5D. The mean utility value of 0.746 estimated from MABEL was
applied to all patients at all time points in the economic model.
The estimated QALYs in the cetuximab/irinotecan and ASC/BSC
treatment groups were 0.68 and 0.35, respectively.
Cost estimates
The cost results for resource use in the two treatment groups are
presented in Table 3. Over the duration of the model, patients
treated with cetuximab/irinotecan accumulated mean additional
costs of d18901 per patient relative to ASC/BSC patients, of which
d11802 was attributable to cetuximab.
Incremental cost-effectiveness
With additional costs of d18901 per patient and LYG of 0.44 per
patient, the incremental cost per life-year gained with cetuximab/
irinotecan therapy compared with ASC/BSC was d42975 (Table 4).
The incremental cost per QALY gained was d57608 (Table 4).
Sensitivity analyses
Sensitivity analyses were undertaken to capture the statistical
uncertainty of the costs and outcomes estimated in the model. An
additional sensitivity analysis was conducted to determine which
variables have the greatest influence on the results of the economic
model.
A bootstrapping technique was applied to the individual patient-
level data of the pivotal cetuximab/irinotecan study (Cunningham
et al, 2004). The additional costs and LYG with cetuximab/
irinotecan vs ASC/BSC for each of the 2000 bootstrap samples are
plotted on the cost-effectiveness plane in Figure 2. This shows that
cetuximab/irinotecan therapy was associated with additional life-
years compared with ASC/BSC in all simulations of the model.
In order to derive a cost-effectiveness acceptability curve, the
cumulative distribution of the incremental cost-effective ratios
across the 2000 samples is presented in Figure 3. If, for example,
d50000 is accepted as a reasonable value for an additional life-year
for an unmet clinical need, then it can be seen from Figure 3, that
the likelihood of cetuximab/irinotecan being a cost-effective
intervention is greater than 90%.
Table 2 Life-expectancy of patients in the economic evaluation, by treatment group
Treatment group
Life-expectancy
(undiscounted) Reference
Life years gained
(discounted
a)
Incremental
life years gained
of cetuximab/irinotecan
Cetuximab/irinotecan 11.01 months Cunningham et al (2004) with after adjustments for censored patients 0.9120
Cetuximab monotherapy 9.64 months Cunningham et al (2004) with after adjustments for censored patients 0.8003 0.1116
ASC/BSC 5.64 months Cetuximab monotherapy with adjustment for treatment
effect based on Cunningham et al (1998) (5.64¼9.64/1.71)
0.4722 0.4398
aLife years are discounted at 3.5% per annum consistent with NICE recommendations.
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Figure 1 Modelled survival curves by treatment group.
Table 3 Total costs by treatment group estimated in the economic
model
Resource item
Cetuximab/
irinotecan ASC/BSC Incremental
Cetuximab costs d11802 d0 d11802
Irinotecan costs d3593 d0 d3593
Other chemotherapy costs d0 d1680  d1680
Administration costs d4300 d467 d3832
Other resource costs d2574 d1221 d1353
Total costs d22270 d3368 d18901
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to ascertain the cost-effectiveness of cetuximab/irinotecan in
discrete scenarios. Variations in assumptions regarding costs and
outcomes were examined in order to establish the strongest result
drivers of the model and to verify the robustness of the primary
results. Sensitivity analyses involving health outcome and cost
variables are shown in Table 5. Of the health outcomes variables
employed within the economic model, the cost-effectiveness of
cetuximab/irinotecan is most sensitive to the survival adjustment
factor. Of the various cost assumptions employed within the
economic model, cost-effectiveness was most sensitive to the cost
of cetuximab.
DISCUSSION
Cetuximab in combination with irinotecan is licensed for the
treatment of patients who have progressed after irinotecan
therapy. In the UK, treatment with cetuximab/irinotecan is likely
to be in the third-line setting, as irinotecan and oxaliplatin are
currently recommended by NICE in the first- and second-line
settings (NICE Technology Assessment no. 91, 2005). However,
second-line usage may potentially be appropriate in a proportion
of patients, for instance where oxaliplatin has been used adjuvantly
and irinotecan used first-line. There are currently no standard
therapeutic options for the third-line treatment of metastatic CRC,
Table 4 Incremental cost-effectiveness ratios estimated in the model
Treatment group Total costs Life-years gained
Incremental cost
per life-year gained QALYs gained
Incremental cost
per QALY gained
Cetuximab/irinotecan d22270 0.9120 0.6803
ASC/BSC d3368 0.4722 0.3522
Incremental d18901 0.4398 d42975 0.3281 d57608
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Figure 2 Scatter plot showing incremental costs of cetuximab/irinotecan
over ASC/BSC.
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Table 5 Incremental cost-effectiveness of cetuximab/irinotecan over ASC/BSC resulting from one-way sensitivity analyses involving health outcomes
variables
Description of sensitivity analysis
Value of
variable/assumption
in base case
Value of
variable/assumption
in sensitivity analysis
Incremental
costs
Incremental
life-years gained
Incremental cost
per life-year
gained
Base case — — d18901 0.4398 d42975
Approximate proportion of ASC/BSC patients
who receive chemotherapy
31% 20% d19638 0.4398 d44649
Approximate proportion of ASC/BSC patients
who receive chemotherapy
31% 40% d18288 0.4398 d41581
Survival adjustment factor to BOND monotherapy data
in estimation of ASC/BSC survival
1.71 1.50 d18732 0.3747 d49999
Survival adjustment factor to BOND monotherapy data
in estimation of ASC/BSC survival
1.71 2.00 d19078 0.5076 d37587
Cost of cetuximab vial d136.50 d90.00 d14881 0.4398 d33834
Cost of chemotherapy administration d255.54 d500 d22568 0.4398 d51311
Cost of chemotherapy administration d255.54 d50 d15819 0.4398 d35967
Cost of BSC while receiving cetuximab/irinotecan (weekly) d59.70 d100 d19602 0.4398 d44568
Cost of BSC while receiving cetuximab/irinotecan (weekly) d59.70 d1 d17881 0.4398 d40656
Cost of BSC while receiving other chemotherapy (weekly) d50.00 d100 d19174 0.4398 d43596
Cost of BSC while receiving other chemotherapy (weekly) d50.00 d1 d18634 0.4398 d42367
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san area of unmet clinical need. Antibody therapy with cetuximab
in combination with irinotecan offers a potentially effective
therapeutic intervention for these patients. However, the routine
introduction of such a treatment in this indication requires the
demonstration of efficacy and cost-effectiveness compared with
current treatment practice.
In this analysis, modelling was employed to extrapolate survival
as a parameter to assess the cost-effectiveness of combination
cetuximab/irinotecan therapy. Overall survival was not the
primary end-point of the pivotal cetuximab/irinotecan study
(Cunningham et al, 2004) and further definitive survival studies
are underway. Different statistical approaches may be applied to
survival modelling, and in the case of this analysis, involved the
imputation of survival data for both treatment arms in the BOND
study to account for censored values. Other statistical approaches,
such as the Weibull technique, are feasible and all have inherent
limitations. In the absence of survival data from a direct
comparison of irinotecan in combination with cetuximab vs
BSC/ASC, an indirect comparison and survival modelling was
necessary. Although this poses some drawbacks, the use of a single
randomised controlled trial as a vehicle for economic analysis also
has limitations and may lead to a partial and limited analysis to
inform decision making. Furthermore, the health-economic
parameters required for cost-effectiveness analyses, such as
health-related utilities, treatment effects, resource use and costs,
are often absent or highly uncertain from early clinical trials of
new chemical entities. The most appropriate framework for
economic analysis is evidence synthesis and decision modelling,
where all available data impacts upon the specific decision
problem and may sometimes involve indirect comparisons
(Sculpher and Claxton, 2005). In addition, new treatments in
oncology offer particular methodological problems for cost-
effectiveness analyses as (i) new agents often add a new element
in a sequential treatment pathway and (ii) the standard
comparator is either absent or highly variable across treatment
centres and national healthcare systems.
The choice of the comparator for the indirect comparison was
drawn from a trial of irinotecan vs supportive care in patients
failing first-line 5-FU-based chemotherapy (Cunningham et al,
1998). This was selected principally, as the supportive care arm
represented the appropriate group for the comparator of ASC/BSC
where 31% of the patients had received ASC. Two other trials of
chemotherapy in the second/subsequent-line treatment vs suppor-
tive care for of metastatic CRC (Barni et al, 1995; Rao et al, 2004)
were considered inappropriate proxies in this analysis as the
supportive care arms comprised BSC alone and no ASC. Of note,
survival figures differed between these studies such that use of
alternative studies may have led to different cost-effectiveness
outcomes such as cost per QALY. However, caution should be
exercised in such cross-study comparisons and implications for
cost-effectiveness owing to trial heterogeneity and differences in
baseline patient characteristics. A full discussion of the potential
pitfalls of the various methodologies that can be employed in this
context is beyond the scope of this article, but is well documented
elsewhere (http://nice.org.uk/page.aspx?o¼325816).
The incremental cost per life-year gain of d42975 for cetuximab/
irinotecan is relatively high compared with other health-care
interventions. However, this result should be considered in the
context of a number of factors specific to this therapy and patient
population, with limited therapeutic options and a generally low
life-expectancy. The economic model showed that cetuximab/
irinotecan nearly doubles patient life-expectancy (0.91 life-years vs
0.47 life-years). Camidge et al (2005) have recently proposed that
the proportion of life-saved should be a consideration in decision
making – over and above the absolute level of life-saved. Many
disease types shorten life to a greater or lesser extent; if an
expensive new treatment allows a terminal cancer patient to live 3
months longer, then it seems inappropriate that this should be
ascribed the same low value-for-money rating (i.e. cost per QALY
threshold) as a treatment that provides the same incremental
survival benefit in the context of a chronic condition [Camidge
et al, 2005]. Similar arguments have previously been proposed by
others (Brouwer and van Hout, 1998; Waugh and Scott, 1998). For
patients with a poor prognosis, the absolute level of life-saved will
likely be relatively low. The concept of ascribing higher cost-
effectiveness thresholds to patients with lower life-expectancy is
consistent with the ‘rule of rescue’, which applies greater value to
therapies for patients with poor prognosis and few available
alternatives and which are life-prolonging.
The incremental cost per QALY gained estimated in this analysis
(d57608) is also relatively high. Again, this result should be
interpreted in the context of the patient population as described in
the previous paragraph, but also in terms of the applicability of
utility values to this patient population. It is not clear that the
EQ-5D instrument does not captures the value that patients apply
to the final stages of their life. In a utility study using the time-
trade-off technique, Petrou et al. estimated a utility value of 0.95 in
metastatic CRC patients (Petrou and Campbell, 1997). Although
this value does not necessarily reflect quality of life per se, it does
capture the value patients place on their remaining life-expectancy.
This is an important consideration for decision makers which
cannot be included in the economic analysis.
With the preceding discussion in mind, and the fact that in the
UK cancer survival is an established national health priority (NHS
Cancer Plan), it is reasonable to consider accepting higher levels of
cost-effectiveness for cetuximab/irinotecan in this patient group.
Traditionally, an incremental cost per life-year gained of d25000–
d30000 has been deemed an acceptable threshold (Rawlins and
Culyer, 2004). If this threshold was increased to d50000 for specific
diseases, or even specific stages of disease, then our analysis
shows that cetuximab/irinotecan would represent value for money.
A recent publicly funded research venture, which sought to
estimate the monetary value of a QALY based upon values
applied in other areas of UK government policy, noted that QALY
gains for life saving/extending health interventions should use a
value of between d45000 and d60000 per QALY (Mason et al,
2006).
In the case of cetuximab, strategies aimed at lowering the
incremental cost per life year gained or QALY have previously
been considered with the specific aim of targeting patients more
likely to benefit from therapy. An association between the presence
and intensity of skin rash and longer survival with cetuximab-
based therapy has been documented (Cunningham et al, 2004;
Perez Soler and Saltz, 2005). In one model, the use of an early CT
scan at 6 weeks could be used to stratify patients for further
treatment; responders would continue therapy, those with
progressive disease would cease therapy and those with stable
disease would continue therapy only if they had developed skin
rash, the so-called continuation rule. Such a strategy would
inevitably reduce the economic impact of treatment. However,
disease stabilisation with cetuximab/irintotecan even in the
absence of skin rash is also an important outcome, particularly
in the face of irinotecan-refractory disease. For the purpose of this
analysis, a continuation rule was not applied. It should also be
noted that currently there are no other validated clinical or
biological markers by which to select patients most likely to
respond to cetuximab, although several studies are underway to
explore this area further. No correlation has been demonstrated
between the presence or intensity of EGFR expression and
response to therapy (Cunningham et al, 2004). There have also
been reports of response to cetuximab/irinotecan in patients
whose tumours do not express EGFR (Chung et al, 2005). The
identification and validation of an appropriate predictive marker
would help to enrich the responding population and potentially
increase cost-effectiveness, which applies equally to other
emerging ‘targeted’ drugs.
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The therapeutic landscape of metastatic CRC has significantly
changed over the last decade with the advent of new cytotoxic
drugs. Their integration with new biologic agents represents an
important scientific and clinical advance and heralds a new
treatment era for the disease. The optimal means by which to
integrate these drugs will continue to evolve, as data emerges from
a multitude of studies that are currently underway. In order that
patients may benefit from current advances in a timely manner,
physicians, patient groups and health commissioners need to
coordinate their assessments and decision-making criteria to
determine the optimal usage for NHS patients of new drugs such as
cetuximab.
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